[go: up one dir, main page]

DK0724642T4 - Nucleinsyrevektor, sammensætning indeholdende en sådan vektor og vaccine til immunisering mod hepatitis - Google Patents

Nucleinsyrevektor, sammensætning indeholdende en sådan vektor og vaccine til immunisering mod hepatitis

Info

Publication number
DK0724642T4
DK0724642T4 DK94914452T DK94914452T DK0724642T4 DK 0724642 T4 DK0724642 T4 DK 0724642T4 DK 94914452 T DK94914452 T DK 94914452T DK 94914452 T DK94914452 T DK 94914452T DK 0724642 T4 DK0724642 T4 DK 0724642T4
Authority
DK
Denmark
Prior art keywords
vector
gene
vaccine
nucleic acid
composition containing
Prior art date
Application number
DK94914452T
Other languages
English (en)
Other versions
DK0724642T3 (da
Inventor
Robert Gerald Whalen
Heather Lynn Davis
Marie-Louise Michel
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Univ D Ottawa University Of Ot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9452149&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0724642(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pasteur Institut, Inst Nat Sante Rech Med, Univ D Ottawa University Of Ot filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK0724642T3 publication Critical patent/DK0724642T3/da
Publication of DK0724642T4 publication Critical patent/DK0724642T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK94914452T 1993-10-22 1994-04-27 Nucleinsyrevektor, sammensætning indeholdende en sådan vektor og vaccine til immunisering mod hepatitis DK0724642T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9312659A FR2711670B1 (fr) 1993-10-22 1993-10-22 Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
PCT/FR1994/000483 WO1995011307A1 (fr) 1993-10-22 1994-04-27 Vecteur nucleotidique, composition le contenant et vaccin pour l'immunisation a l'encontre d'une hepatite

Publications (2)

Publication Number Publication Date
DK0724642T3 DK0724642T3 (da) 2006-12-18
DK0724642T4 true DK0724642T4 (da) 2010-10-25

Family

ID=9452149

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94914452T DK0724642T4 (da) 1993-10-22 1994-04-27 Nucleinsyrevektor, sammensætning indeholdende en sådan vektor og vaccine til immunisering mod hepatitis

Country Status (11)

Country Link
US (2) US6635624B1 (da)
EP (1) EP0724642B2 (da)
AT (1) ATE335831T1 (da)
AU (1) AU6681794A (da)
CA (1) CA2174652C (da)
DE (1) DE69434820T3 (da)
DK (1) DK0724642T4 (da)
ES (1) ES2270416T5 (da)
FR (1) FR2711670B1 (da)
PT (1) PT724642E (da)
WO (1) WO1995011307A1 (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (fr) * 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5837534A (en) * 1995-11-14 1998-11-17 The Board Of Regents Of The University Of Texas System Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells
US5981274A (en) * 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
CN1044092C (zh) 1997-02-26 1999-07-14 上海医科大学 抗原－抗体－重组dna复合型疫苗
FR2767337B1 (fr) 1997-08-14 2002-07-05 Pasteur Institut Sequences nucleiques de polypeptides exportes de mycobacteri es, vecteurs les comprenant et applications au diagnostic et a la prevention de la tuberculose
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
CN1280619A (zh) 1997-11-28 2001-01-17 根瑟特公司 沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US20040062775A1 (en) 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
US6759193B2 (en) 1999-07-28 2004-07-06 The Government Of The Republic Of Singapore Detection of human hepatitis B virus surface antigen mutants by specific amplification and its application on gene chip
EP1311288A1 (en) * 2000-01-20 2003-05-21 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US7001760B2 (en) * 2000-04-20 2006-02-21 Wang-Schick Ryu Hepatitis B virus vectors for gene therapy
MXPA05004588A (es) * 2002-10-29 2005-12-14 Coley Pharmaceutical Group Ltd Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
WO2004087203A2 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
WO2005007672A2 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (tlr) antagonists
CN1704475A (zh) * 2004-05-31 2005-12-07 成都生物制品研究所 羧端含前s2免疫决定簇的乙肝表面抗原融合基因及蛋白质
US7803910B2 (en) 2005-01-24 2010-09-28 Merck Serono S.A. Soluble CD164 polypeptides
CA2636424A1 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
WO2010027818A2 (en) 2008-08-25 2010-03-11 Dana-Farber Cancer Institute, Inc. Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
WO2014127825A1 (en) 2013-02-21 2014-08-28 Boehringer Ingelheim Vetmedica Gmbh H5 proteins of h5n1 influenza virus for use as a medicament
US9987348B2 (en) 2013-09-25 2018-06-05 Zoetis Services Llc PCV2B divergent vaccine composition and methods of use
KR20160132494A (ko) 2014-04-03 2016-11-18 베링거잉겔하임베트메디카인코퍼레이티드 돼지 유행성 설사 바이러스 백신
JP7046607B2 (ja) 2015-08-31 2022-04-04 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 先天性振戦に対するペスチウイルスワクチン
JP2018526454A (ja) 2015-09-16 2018-09-13 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド ブタコレラ菌−ネズミチフス菌ワクチン
CA3036291A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New ehv insertion site orf70
JP7187448B2 (ja) 2016-09-20 2022-12-12 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 新しいプロモーター
UY37408A (es) 2016-09-20 2018-03-23 Boehringer Ingelheim Vetmedica Gmbh Vacuna de vectores contra el virus de la gripe “a” porcina
KR102618127B1 (ko) 2016-09-20 2023-12-27 베링거잉겔하임베트메디카게엠베하 개 아데노바이러스 벡터
TWI788309B (zh) 2016-11-03 2023-01-01 德商百靈佳殷格翰維美迪加股份有限公司 抗豬小病毒及豬生殖與呼吸道症候群病毒之疫苗及其製造方法
TWI781962B (zh) 2016-11-03 2022-11-01 德商百靈佳殷格翰維美迪加股份有限公司 抗豬小病毒疫苗
EP3573655A2 (en) 2017-01-30 2019-12-04 Boehringer Ingelheim Animal Health USA Inc. Porcine coronavirus vaccines
CN110869047B (zh) 2017-07-12 2025-01-10 勃林格殷格翰动物保健美国有限公司 塞内卡病毒a免疫原性组合物及其方法
AR113124A1 (es) 2017-09-23 2020-01-29 Boehringer Ingelheim Vetmedica Gmbh Sistema de expresión de paramyxoviridae
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
AU2019223768A1 (en) 2018-02-23 2020-08-27 Boehringer Ingelheim Animal Health USA Inc. Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
MX2020009724A (es) 2018-03-19 2020-10-08 Boehringer Ingelheim Vetmedica Gmbh Ehv novedoso con ul18 y/o ul8 inactivados.
EA202092165A1 (ru) 2018-03-19 2021-02-25 Бёрингер Ингельхайм Ветмедика Гмбх Новый ehv сайт инсерции ul43
US11957746B2 (en) 2018-03-26 2024-04-16 Boehringer Ingelheim Animal Health USA Inc. Method of producing an immunogenic composition
WO2020058327A1 (en) 2018-09-20 2020-03-26 Boehringer Ingelheim Vetmedica Gmbh Modified pedv spike protein
TW202026010A (zh) 2018-09-20 2020-07-16 德商百靈佳殷格翰維美迪加股份有限公司 抗豬流行性下痢之鼻內載體疫苗
US11858962B2 (en) 2020-02-06 2024-01-02 Boehringer Ingelheim Vetmedica Gmbh Polypeptides useful for detecting anti-rhabdovirus antibodies
US20220160864A1 (en) 2020-10-05 2022-05-26 Boehringer Ingelheim Animal Health USA Inc. Fusion protein comprising circoviridae capsid protein, and chimeric virus-like particles composed thereof
TW202229314A (zh) 2020-10-05 2022-08-01 德商百靈佳殷格翰維美迪加股份有限公司 用於針對輪狀病毒疫苗接種之融合蛋白質
WO2023194913A1 (en) 2022-04-05 2023-10-12 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for vaccination against rotavirus

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US565203A (en) 1896-08-04 espersen
LU88257I2 (da) 1978-12-22 1994-02-03
DE2942780A1 (de) 1979-10-23 1981-05-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Eukaryotische zellen, eukaryotische protoplasten und vielzellige eukaryotische lebende organismen mit einem gehalt an durch lipidvesikel eingebrachter dna, verfahren zu ihrer herstellung von gen-produkten, zur immunisierung und zur behebung genetisch bedingter defekte
US4803164A (en) 1981-08-31 1989-02-07 Genentech, Inc. Preparation of hepatitis b surface antigen in yeast
US4547367A (en) 1983-12-20 1985-10-15 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis B core antigen vaccine
FR2560890B1 (fr) 1984-03-07 1987-10-16 Grp Genie Genetique Composition utile pour la fabrication de vaccins contenant des particules portant l'antigene de surface du virus de l'hepatite b et le recepteur de l'albumine serique humaine polymerisee, cellules animales capables de produire de telles particules et procede pour leur obtention
JPS6137738A (ja) 1984-07-31 1986-02-22 Tetsuo Nakamura Ｂ型肝炎ワクチン
BR8404286A (pt) * 1984-08-28 1986-04-08 Sergio Landau Seringa hipodermica a pressao
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
CA1268437A (en) 1984-12-21 1990-05-01 Haruo Fujita Method for purification of hbc antigen and method for measurement of hbc antibody by using said purified hbc antigen
US4957869A (en) 1985-07-12 1990-09-18 New York University Immunogenic peptide corresponding to P. vivax CS protein
WO1988006185A1 (en) * 1987-02-11 1988-08-25 Scripps Clinic And Research Foundation Retroviral expression vectors and methods for producing hbv antigens
US5256767A (en) 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
US5256553A (en) 1987-10-09 1993-10-26 Immunex Corporation Multiple promoter transforming retroviral vectors
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5786189A (en) 1989-11-29 1998-07-28 Smithkline Beecham Biologicals (S.A.) Vaccine
WO1992006212A1 (en) * 1990-09-28 1992-04-16 Smithkline Beecham Corporation Enhanced expression of viral proteins in drosophila cells
JPH06500128A (ja) 1991-05-08 1994-01-06 シュバイツ・ゼルム―・ウント・インプフィンスティテュート・ベルン 免疫刺激及び免疫増強性再構成インフルエンザウイロソーム及びそれを含有するワクチン
WO1993000103A1 (en) 1991-06-21 1993-01-07 The Wistar Institute Of Anatomy And Biology Chimeric envelope proteins for viral targeting
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
HU209110B (en) 1991-12-02 1994-03-28 Foeldtani Kutato Es Furo Kft Process for the local treatment of soil, particularly for the examination and cleaning of contaminated soil
PT625204E (pt) 1992-02-04 2002-10-31 Chiron Corp Terapeutica da hepatite
GB9204274D0 (en) * 1992-02-28 1992-04-08 Wellcome Found Novel peptides
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5620896A (en) 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5985847A (en) 1993-08-26 1999-11-16 The Regents Of The University Of California Devices for administration of naked polynucleotides which encode biologically active peptides
EP0714308A4 (en) 1993-08-26 1998-07-29 Univ California METHOD, COMPOSITIONS AND DEVICES FOR THE ADMINISTRATION OF NAKED POLYNUCLEOTIDS, WHICH ENCODE FOR BIOLOGICALLY ACTIVE PEPTIDES
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US5814617A (en) 1994-10-07 1998-09-29 The United States Of America As Represented By The Secretary Of The Navy Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
GB9503863D0 (en) 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5565023A (en) * 1995-11-15 1996-10-15 Fusion All-Sport Grip, Inc. Moisture absorbing and frictional grip enhancing composition and method of forming same
CA2244946C (en) 1996-01-30 2010-04-13 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
FR2790955B1 (fr) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
US20020142978A1 (en) 2000-04-07 2002-10-03 Eyal Raz Synergistic improvements to polynucleotide vaccines
CN1822856B (zh) 2003-07-11 2010-04-28 英特塞尔股份公司 Hcv疫苗
WO2005039633A1 (de) 2003-10-24 2005-05-06 Mologen Ag Mittel zur behandlung von infektionen mit leishmanien

Also Published As

Publication number Publication date
CA2174652A1 (fr) 1995-04-27
US20050042203A1 (en) 2005-02-24
ATE335831T1 (de) 2006-09-15
EP0724642B1 (fr) 2006-08-09
DE69434820T2 (de) 2007-03-29
WO1995011307A1 (fr) 1995-04-27
ES2270416T5 (es) 2010-11-30
FR2711670B1 (fr) 1996-01-12
AU6681794A (en) 1995-05-08
FR2711670A1 (fr) 1995-05-05
US6635624B1 (en) 2003-10-21
DK0724642T3 (da) 2006-12-18
CA2174652C (fr) 2010-03-30
DE69434820T3 (de) 2011-02-24
EP0724642B2 (fr) 2010-07-21
US7825097B2 (en) 2010-11-02
ES2270416T3 (es) 2007-04-01
DE69434820D1 (de) 2006-09-21
EP0724642A1 (fr) 1996-08-07
PT724642E (pt) 2006-12-29

Similar Documents

Publication Publication Date Title
DK0724642T3 (da) Nukleinsyrevektor, sammensætning indeholdende en sådan vektor og vaccine til immunisering mod hepatitis
HK1046694A1 (zh) 干擾素-α蛋白作為FC融合蛋白的表達和運輸
BR0007414A (pt) Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
ES8500322A1 (es) Un metodo de modificar un virus para conferirle una nueva funcion biologica.
EP0331939A3 (en) Method and compositions for conferring resistance to retroviral infection
NO173741C (no) DNA-sekvens for modifisert protein C, vektor inneholdende denne, patte-dyrceller transfektert med vektorer, og fremgangsmaate for fremstilling av nevnte protein
DE69637738D1 (de) Herstellung von einer Immunantwort gegen Prostat-spezifisches Antigen (SPA)
ATE323169T1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
DE69627698T2 (de) Eine in kaskaden verlaufende vervielfältigungsreaktion von nukleinsäuren
FI934937A (fi) Sekvenser av hcv-genom foer diagnostisk och terapi
MXPA02005525A (es) Clones infecciosos.
AUPN477695A0 (en) Gene therapy
DE69837708D1 (de) Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion
HUT71847A (en) Dna molecules encoding aminopeptidase enzymes, vectors and transgenic cells containing dna molecules, immunogenic polypeptides encoding by dna molecules, vaccines against helminth infections containing these peptides and process for the preparation ...
KR930701610A (ko) 미생물의 세포, 조직 또는 숙주 지향성을 변화시키는 방법, 이 방법으로 수득된 재조합 미생물, 및 의학 및 수의학분야에서 이들을 사용하는 방법
DK0651806T3 (da) Vacciner imod katteimmundeficiensvirus (FIV)
WO1998059063A3 (en) Bovine adenovirus type 3 genome
EP0256677A3 (en) Pseudorabies virus recombinants and their use in the production of proteins
DK0691404T3 (da) Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf
WO1987007472A3 (en) A dna sequence encoding the mas oncogene, polypeptides encoded therefrom, and diagnostic and other methods based thereon
AU686000B2 (en) Infectious peritonitis vaccine
ES2367245T8 (es) Virus recombinante que expresa adn foráneo que codifica cd80 felino, cd28 felino, ctla-4felino o cd86 felino y usos del mismo.
AU3964189A (en) Complete nucleotidic sequence of the complementary dna of the genomic rna of the potyvirus, genes coding for the potyvirus capside protein and application of said genes to the creation of potyvirus-resistant transgenic plants
EP0789563A4 (en) Vaccines against the hepatitis virus
TH1348A (th) การประดิษฐ์ไวรัสที่มีโปรตีนพื้นผิวเป็นรีคอมบิแนนท์โปรตีน